Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies

2018 ◽  
Vol 25 (8) ◽  
pp. 894-903 ◽  
Author(s):  
M. Li ◽  
Y. Gan ◽  
C. Fan ◽  
H. Yuan ◽  
X. Zhang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Non Hodgkin Lymphoma ◽  
B Virus

scholarly journals Sa1020 Hepatitis B Virus Infection and Risk of Non-Hodgkin Lymphoma: A Meta-Analysis of Case-Control Studies

2013 ◽  
Vol 144 (5) ◽  
pp. S-974 ◽  
Author(s):  
Rajan Kanth ◽  
Anupama Inaganti ◽  
Naga Swetha Samji ◽  
Sarah D. Komanapalli ◽  
Brian B. Borg ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Case Control ◽  
Hepatitis B Virus Infection ◽  
Case Control Studies ◽  
Non Hodgkin Lymphoma ◽  
B Virus

Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis

2013 ◽  
Vol 57 (3) ◽  
pp. 209-214 ◽  
Author(s):  
Hua-Jie Dong ◽  
Ling-Na Ni ◽  
Gui-Feng Sheng ◽  
Hong-Lei Song ◽  
Jian-Zhong Xu ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Hbv Reactivation ◽  
Non Hodgkin Lymphoma ◽  
B Virus

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma

Infection ◽  
2012 ◽  
Vol 41 (1) ◽  
pp. 225-229 ◽  
Author(s):  
Gilda Tonziello ◽  
Marintonietta Pisaturo ◽  
Antonello Sica ◽  
Maria Giovanna Ferrara ◽  
Caterina Sagnelli ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Hepatitis B Virus Infection ◽  
Occult Hepatitis ◽  
Non Hodgkin Lymphoma ◽  
B Virus ◽  
Occult Hepatitis B ◽  
Lamivudine Prophylaxis

scholarly journals Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7481 ◽  
Author(s):  
Yu-Fen Tsai ◽  
Ching-I Yang ◽  
Jeng-Shiun Du ◽  
Ming-Hui Lin ◽  
Shih-Hao Tang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Hbv Reactivation ◽  
Virus Reactivation ◽  
Non Hodgkin Lymphoma ◽  
B Virus ◽  
Hepatitis Flare

Background Hepatitis B virus (HBV) reactivation with a hepatitis flare is a common complication in lymphoma patients treated with immunotherapy and/or chemotherapy. Anti-HBV prophylaxis is suggested for non-Hodgkin lymphoma (NHL) patients undergoing rituximab therapy, even those with resolved HBV infection. Since anti-HBV prophylaxis for patients with resolved HBV infection is not covered by national health insurance in Taiwan, a proportion of these patients receive no prophylaxis. In addition, late HBV reactivation has emerged as a new issue in recent reports, and no consensus has been reached for the optimal duration of antiviral prophylaxis. Thus, the aim of our study was to investigate the incidence and outcomes of HBV reactivation in NHL patients in a real-world setting and to study the frequency of late HBV reactivation. Materials Non-Hodgkin lymphoma patients who received rituximab and/or chemotherapy at our institute between January 2011 and December 2015 and who were hepatitis B surface antigen (HBsAg)- or hepatitis B core antibody (HBcAb)-positive were reviewed retrospectively. Results A total of 388 patients were screened between January 2011 and December 2015. In total, 196 patients were excluded because HBsAg was not assessed, HBcAb was negative or not assessed, or they were not treated with immunosuppressive therapy. Finally, the retrospective study included 62 HBsAg-positive NHL patients and 130 NHL patients with resolved HBV infection (HBsAg-negative and HBcAb-positive). During a median 30.5-month follow-up period, seven patients experienced HBV reactivation, five of whom had a hepatitis flare. The incidence of HBV reactivation did not significantly differ between the HBsAg-positive patients and the resolved HBV infection population without anti-HBV prophylaxis (4.8% vs. 3.1%, P = 0.683). All patients with HBV reactivation were exposed to rituximab. Notably, late HBV reactivation was not uncommon (two of seven patients with HBV reactivation events, 28.6%). Hepatitis B virus reactivation did not influence the patients’ overall survival. An age ≥65 years and an advanced disease stage were independent risk factors for poorer overall survival. Conclusion The incidence of HBV reactivation was similar between the HBsAg-positive patients with antiviral prophylaxis and the resolved HBV infection population without anti-HBV prophylaxis. All HBV reactivation events occurred in NHL patients exposed to rituximab. Late reactivation was not uncommon. The duration of regular liver function monitoring for more than 1 year after immunosuppressive therapy or after withdrawal of prophylactic antiviral therapy should be prolonged. Determining the exact optimal duration of anti-HBV prophylaxis is warranted in a future prospective study for NHL patients treated with rituximab-containing therapy.

451 High prevalence of hepatitis B virus infection in B-cell non-hodgkin lymphoma

2006 ◽  
Vol 44 ◽  
pp. S168-S169
Author(s):  
P. Borentain ◽  
P. Colson ◽  
A. Motte ◽  
V. Moa ◽  
M. Henry ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Hepatitis B Virus Infection ◽  
Non Hodgkin Lymphoma ◽  
B Virus ◽  
High Prevalence

The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma

2017 ◽  
Vol 24 (10) ◽  
pp. 885-894 ◽  
Author(s):  
C.-E. Huang ◽  
Y.-H. Yang ◽  
Y.-Y. Chen ◽  
J.-J. Chang ◽  
K.-J. Chen ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Hepatitis B Virus Infection ◽  
Non Hodgkin Lymphoma ◽  
B Virus ◽  
The Impact

scholarly journals Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland – a report of the Polish Lymphoma Research Group

2020 ◽  
Vol 16 (1) ◽  
pp. 157-161
Author(s):  
Ewa Kalinka ◽  
Joanna Drozd-Sokołowska ◽  
Anna Waszczuk-Gajda ◽  
Joanna Barankiewicz ◽  
Elżbieta Zalewska ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hodgkin Lymphoma ◽  
Research Group ◽  
Non Hodgkin Lymphoma ◽  
B Virus ◽  
Virus Screening
Sign in / Sign up

Export Citation Format

Share Document